| First Author | Kim HJ | Year | 2015 |
| Journal | Exp Cell Res | Volume | 334 |
| Issue | 2 | Pages | 301-9 |
| PubMed ID | 25814363 | Mgi Jnum | J:221958 |
| Mgi Id | MGI:5643795 | Doi | 10.1016/j.yexcr.2015.03.008 |
| Citation | Kim HJ, et al. (2015) Lipocalin-2 inhibits osteoclast formation by suppressing the proliferation and differentiation of osteoclast lineage cells. Exp Cell Res 334(2):301-9 |
| abstractText | Lipocalin-2 (LCN2) is a member of the lipocalin superfamily and plays a critical role in the regulation of various physiological processes, such as inflammation and obesity. In this study, we report that LCN2 negatively modulates the proliferation and differentiation of osteoclast precursors, resulting in impaired osteoclast formation. The overexpression of LCN2 in bone marrow-derived macrophages or the addition of recombinant LCN2 protein inhibits the formation of multinuclear osteoclasts. LCN2 suppresses macrophage colony-stimulating factor (M-CSF)-induced proliferation of osteoclast precursor cells without affecting their apoptotic cell death. Interestingly, LCN2 decreases the expression of the M-CSF receptor, c-Fms, and subsequently blocks its downstream signaling cascades. In addition, LCN2 inhibits RANKL-induced osteoclast differentiation and attenuates the expression of c-Fos and nuclear factor of activated T cells c1 (NFATc1), which are important modulators in osteoclastogenesis. Mechanistically, LCN2 inhibits NF-kappaB signaling pathways, as demonstrated by the suppression of IkappaBalpha phosphorylation, nuclear translocation of p65, and NF-kappaB transcriptional activity. Thus, LCN2 is an anti-osteoclastogenic molecule that exerts its effects by retarding the proliferation and differentiation of osteoclast lineage cells. |
